Skip to content


Clinical Trials

Pentucket Medical is committed in improving and offering advanced treatments. We do this by being involved in several clinical trials. These trials have brought about successful outcomes such as:

  • 3 trials for atrial fibrillation where the drugs were approved by the FDA
  • 2 trials for heart failure where the drug was approved by the FDA
  • 1 trial that helped change the guidelines for post heart attack patients.

We are currently enrolling participants who have:

  • Had Heart failure
  • Diabetes
  • Had a prior heart attack
  • High cholesterol

If you are interested in participating in one of our clinical trials click the links below Active Studies.


To find out whether you are eligible to participate in one of these studies, please contact the Clinical Research Office at (978) 469-5494.

Active Studies

Clinical trials are entirely voluntary and patients may withdraw at any time, for any reason. We are currently participating in the following studies:


A Randomized, Double-blind, Placebo-controlled, Event-driven trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infraction Patients with Type 2 Diabetes or Metabolic Syndrome.

Trials Closed to Enrollment

Currently in follow up phase:


A double-blind, randomized, placebo-controlled, multicenter study assessing the impact of additional ldl-chloesterol reduction on major cardiovascular events when used in combination with statin therapy in patients with clinically evident cardiovascular disease


A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP


Dapagliflozin Effect on Cardiovascular Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes